

Japan's MHLW lifts prescription period limitation for Daiichi Sankyo's antiplatelet agent

01 June 2015 | News | By BioSpectrum Bureau

Japan's MHLW lifts prescription period limitation for Daiichi Sankyo's antiplatelet agent



Based on a notification received from the Japanese Ministry of Health, Labour and Welfare, Daiichi Sankyo Company Limited has announced that the antiplatelet agent Efient 3.75mg/5mg Tablets (Prasugrel Hydrochloride), which was launched in Japan in May 2014, has had its prescription period limitation of 14 days lifted.

Efient is an oral antiplatelet agent discovered by Daiichi Sankyo and its Japanese research partner, Ube Industries Limited. The results of clinical trials in Japanese patients with ischemic heart disease undergoing percutaneous coronary intervention (PCI) demonstrated that Efient reduces the incidence of ischemic events from the perioperative period of PCI by rapidly reducing platelet aggregation activity.

Through the lifting of the prescription period limitation of Efient, Daiichi Sankyo aims to benefit even more patients and healthcare professionals involved with ischemic heart disease therapy.